Damen Carola W N, Israëls Trijn, Caron Huib N, Schellens Jan H M, Rosing Hilde, Beijnen Jos H
Department of Pharmacy & Pharmacology, Slotervaart Hospital/The Netherlands Cancer Institute, Louwesweg 6, 1066 EC Amsterdam, The Netherlands.
Rapid Commun Mass Spectrom. 2009 Mar;23(6):763-74. doi: 10.1002/rcm.3938.
A sensitive, specific and efficient high-performance liquid chromatography/tandem mass spectrometry (HPLC/MS/MS) assay for the simultaneous determination of total vincristine and actinomycin-D concentrations in human plasma and an assay for the determination of unbound vincristine are presented. Electrospray ionization (ESI), atmospheric pressure chemical ionization (APCI) and heated electrospray ionization (H-ESI) were tested as ionization interfaces. For reasons of robustness ESI was chosen followed by tandem mass spectrometry (ESI-MS/MS). For the plasma assay a 30 microL aliquot was protein precipitated with acetonitrile/methanol (50:50, v/v) containing the internal standard vinorelbine and 10 microL volumes were injected onto the HPLC system. To determine unbound vincristine, ultrafiltrate was produced from plasma using 30 kDa centrifugal filter units. The plasma ultrafiltrate was mixed with methanol (50:50, v/v), internal standard vinorelbine was added and 20 microL aliquots were injected onto the HPLC system. Separation was achieved on a 50x2.1 mm i.d. Xbridge C18 column using 1 mM ammonium acetate/acetonitrile (30:70, v/v) adjusted to pH 10.5 with ammonia, run in a gradient with methanol at a flow rate of 0.4 mL/min. HPLC run time was 6 min. The assay quantifies in plasma vincristine from 0.25 to 100 ng/mL and actinomycin-D from 0.5 to 250 ng/mL using plasma sample volumes of only 30 microL. Vincristine in plasma ultrafiltrate can be quantified from 1 to 100 ng/mL. Validation results demonstrate that vincristine and actinomycin-D can be accurately and precisely quantified in human plasma and plasma ultrafiltrate with the presented methods. The assays are now in use to support clinical pharmacological studies in children treated with vincristine and actinomycin-D.
本文介绍了一种灵敏、特异且高效的高效液相色谱/串联质谱(HPLC/MS/MS)法,用于同时测定人血浆中长春新碱和放线菌素-D的总浓度,以及一种测定游离长春新碱的方法。对电喷雾电离(ESI)、大气压化学电离(APCI)和加热电喷雾电离(H-ESI)作为电离接口进行了测试。出于耐用性考虑,选择了ESI,随后是串联质谱(ESI-MS/MS)。对于血浆分析,取30 μL等分试样,用含有内标长春瑞滨的乙腈/甲醇(50:50,v/v)进行蛋白沉淀,取10 μL体积注入HPLC系统。为了测定游离长春新碱,使用30 kDa离心过滤单元从血浆中制备超滤物。将血浆超滤物与甲醇(50:50,v/v)混合,加入内标长春瑞滨,取20 μL等分试样注入HPLC系统。在一根50×2.1 mm内径的Xbridge C18柱上进行分离,使用1 mM醋酸铵/乙腈(30:70,v/v),用氨调节至pH 10.5,以0.4 mL/min的流速用甲醇进行梯度洗脱。HPLC运行时间为6分钟。该分析方法使用仅30 μL的血浆样品体积,可定量血浆中0.25至100 ng/mL的长春新碱和0.5至250 ng/mL的放线菌素-D。血浆超滤物中的长春新碱可定量范围为1至100 ng/mL。验证结果表明,使用所提出的方法可以准确、精确地定量人血浆和血浆超滤物中的长春新碱和放线菌素-D。这些分析方法目前用于支持接受长春新碱和放线菌素-D治疗的儿童的临床药理学研究。